PF-03550096
# PF-03550096

PF-03550096 is a drug that acts as a potent agonist for the $CB_2$ cannabinoid receptor, with good selectivity over $CB_1$ having $K_i$ values of 7nM at $CB_2$ and 1500nM at $CB_1.$ It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome, but has only progressed to animal studies.

